Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-01 am EST
0.0290 CHF   -0.34%
11/21APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival
EQ
11/16Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
EQ
11/14Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Relief Therapeutics Posts Wider Attributable Loss In H1

09/15/2022 | 01:48am EST


ę MT Newswires 2022
All news about RELIEF THERAPEUTICS HOLDING AG
11/21APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the ..
EQ
11/16Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 wit..
EQ
11/14Relief Therapeutics, NRx Pharmaceuticals Sign Deal to Resolve Aviptadil Dispute
MT
11/14Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Defi..
EQ
11/08Relief Therapeutics, NRx Further Extend Stay of Pending Aviptadil Dispute
MT
11/08Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay ..
EQ
11/07Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation ..
CI
11/07Relief Therapeutics' New Aviptadil Formulation Found To Be Stable In Six-month Data
MT
11/07Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 ..
EQ
10/26Relief Therapeutics, NRx Extend Stay For Pending Aviptadil Dispute
MT
More news
Financials
Sales 2022 12,0 M 12,6 M 12,6 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 128 M 135 M 135 M
Capi. / Sales 2022 10,7x
Capi. / Sales 2023 5,57x
Nbr of Employees 10
Free-Float 65,6%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,03 CHF
Average target price 0,32 CHF
Spread / Average Target 1 013%
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Paolo Galfetti Chief Operating Officer & Director
Thomas Plitz Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-53.22%135
MODERNA, INC.-30.74%67 581
IQVIA HOLDINGS INC.-22.73%40 495
LONZA GROUP AG-35.64%38 281
ALNYLAM PHARMACEUTICALS, INC.30.08%27 139
SEAGEN INC.-21.48%22 538